Addex shares are trading lower after the company announced the Phase 2 ADX71149 epilepsy study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standa...

ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS -0.29%

ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS

ADXN

8.24

-0.29%

Addex shares are trading lower after the company announced the Phase 2 ADX71149 epilepsy study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via